Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, randomised study comparing the uptake of rIL-2 [aldesleukin] in HIV-1 infected individuals receiving different combinations of antiemetics and analgesic agents during rIL-2 dosing in ESPRIT: toxicity substudy of ESPRIT: TOXIL-2 substudy.

Next Previous
X
Search
Trial Profile

An open-label, randomised study comparing the uptake of rIL-2 [aldesleukin] in HIV-1 infected individuals receiving different combinations of antiemetics and analgesic agents during rIL-2 dosing in ESPRIT: toxicity substudy of ESPRIT: TOXIL-2 substudy.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldesleukin; Codeine phosphate; Ibuprofen; Metoclopramide; Ondansetron; Paracetamol
  • Indications HIV-1 infections; Nausea and vomiting; Pain
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ESPRIT; ESPRIT TOXIL-2; TOXIL-2

    • Most Recent Events

    • 12 Apr 2012 Biomarkers information updated
    • 11 Apr 2012 Actual patient number is 28 according to ClinicalTrials.gov.
    • 11 Apr 2012 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top